SA Transcripts • Thu, Aug. 14
There is research on this stock available only to PRO subscribers.
Should Basilea Pharmaceutica Be Trading At Twice This Price?
- Basilea Pharmaceutica is looking to get three new drugs to market in the U.S. in a relatively short period of time.
- The antifungal isavuconazole and the antibiotic ceftobiprole could produce over $1.25 billion in peak sales.
- Basilea's pipeline is not particularly deep, leaving little cushion if its lead drugs cannot make it to market in the U.S.
Jun. 12, 2012, 8:19 AM(GSK) is making another bolt-on acquisition to strengthen its lineup, agreeing to pay an initial £146M ($227M) to acquire eczema drug Toctino from Swiss biotech Basilea (BPMUF.PK). GSK will pay another £50M if Toctino passes its Phase III trial and receives FDA approval, and royalties on U.S. sales starting three years after launch. | Comment!
BPMUF vs. ETF Alternatives
Other News & PR